Home > Drugs A – Z > Abciximab (By injection)

Abciximab (By injection)

Prevents blood clots from forming during a procedure to open blocked blood vessels.

What works?

Learn more about the effects of these drugs. The most reliable research is summed up for you in our featured article.

Abciximab is used to lessen the chance of heart attack in people who need percutaneous coronary intervention (PCI), a procedure to open blocked arteries of the heart. A heart attack may occur when a blood vessel in the heart is blocked by a blood clot. Blood clots can sometimes form during PCI. Abciximab reduces the chance that a harmful clot will form by preventing certain cells in the blood… Read more
Brand names include
Reopro
Drug classes About this
Platelet Aggregation Inhibitor

What works? Research summarized

Evidence reviews

Intracoronary versus intravenous administration of abciximab in patients with acute coronary syndrome: a meta-analysis

BACKGROUND: Abciximab is a widely used adjunctive therapy for acute coronary syndrome (ACS). However, the effect of intracoronary (i.c.) administration of abciximab on cardiovascular events remains unclear when compared with intravenous (i.v.) therapy.

Efficacy and safety of abciximab in diabetic patients who underwent percutaneous coronary intervention with thienopyridines loading: a meta-analysis

BACKGROUND: It has been controversial whether abciximab offered additional benefits for diabetic patients who underwent percutaneous coronary intervention (PCI) with thienopyridines loading.

Intracoronary abciximab reduces death and major adverse cardiovascular events in acute coronary syndromes: a meta-analysis of clinical trials

BACKGROUND: Successful reperfusion of epicardial coronary arteries does not necessarily result in actual myocardial perfusion. Local intracoronary (IC) delivery of GP IIb/IIIa inhibitors (GPI) has been proposed to achieve further clinical efficacy when compared to standard intravenous (IV) administration. However clinical trials have shown conflicting results. The aim of the present study was to compare IC with IV abciximab administration on mortality and MACEs in patients with ACS undergoing PCI.

See all (59)

Summaries for consumers

Glycoprotein IIb‐IIIa inhibitors for acute ischaemic stroke

Question: We wanted to evaluate the safety and effectiveness of GP IIb‐IIIa inhibitors, alone or in combination with thrombolytic agents, in individuals with acute ischaemic stroke.

Drugs used as add‐on therapy to heart procedure following heart attack

Acute myocardial infarction (AMI), or heart attack, is one of the major causes of mortality worldwide. Approximately one‐third of people suffering heart attacks die before they reach the hospital. Primary percutaneous coronary intervention (PPCI) is a procedure whereby the coronary artery is widened without surgery, using a stent. Although this procedure restores blood flow through the coronary artery, perfusion through all areas of the heart may not occur. This is known as no‐reflow. To try to resolve this problem, healthcare workers have tried drugs such as adenosine and verapamil as add‐on treatment. We include 11 studies in this review with a total of 1027 participants. Ten studies compared adenosine or placebo as an addition to PPCI, and one compared verapamil or placebo.

Drugs to prevent the re‐occurrence of narrowing of blood vessels in peripheral arterial disease after the blood vessels have been surgically widened

Peripheral arterial disease of leg arteries can progressively cause leg pain on walking, pain at rest, ulcers and gangrene because of reduced blood flow. An inflatable balloon catheter inserted into the artery is used to widen and unblock the affected artery (termed angioplasty) yet reoccurrence of narrowing (restenosis) or obstruction (reocclusion) frequently occurs because of platelet clumping (aggregation) and activated blood clotting in the damaged blood vessel. This review of 22 randomised clinical trials, with a combined total of 3529 patients, set out to determine if any drug was more effective than another in preventing occlusion or restenosis of the artery after the blood vessels have been surgically widened. For the majority of comparisons, only one study was available. Evidence suggests that some drugs which reduce platelet aggregation, such as higher‐dose aspirin, can reduce the rate of reocclusion six months after surgery, but evidence on associated side effects and for longer‐term restenosis rates is scarce. There is also some evidence of variation in effect according to different drugs, with reocclusion/restenosis rates lower in people taking cilostazol compared with ticlopidine 12 months after surgery and, in patients with more severe disease, those taking low molecular weight heparin in addition to aspirin compared with aspirin alone. Batroxobin plus aspirin compared with aspirin alone may be an effective treatment in diabetic patients. However, available trials are generally small and of variable quality and side effects of drugs are not consistently addressed. Further good quality, large‐scale randomised controlled trials, grouped by severity of disease, are required.

PubMed Health Blog...

read all...